Comparing Cost of Revenue Efficiency: AstraZeneca PLC vs Biogen Inc.

AstraZeneca vs. Biogen: Cost Efficiency Battle Unveiled

__timestamp	AstraZeneca PLC	Biogen Inc.
Wednesday, January 1, 2014	5842000000	1171036000
Thursday, January 1, 2015	4646000000	1240400000
Friday, January 1, 2016	4126000000	1478700000
Sunday, January 1, 2017	4318000000	1630000000
Monday, January 1, 2018	4936000000	1816300000
Tuesday, January 1, 2019	4921000000	1955400000
Wednesday, January 1, 2020	5299000000	1805200000
Friday, January 1, 2021	12437000000	2109700000
Saturday, January 1, 2022	12391000000	2278300000
Sunday, January 1, 2023	8040000000	2533400000
Monday, January 1, 2024	10207000000	0

In pursuit of knowledge

A Tale of Two Giants: AstraZeneca vs. Biogen

In the ever-evolving pharmaceutical industry, cost efficiency is a critical metric for success. From 2014 to 2023, AstraZeneca PLC and Biogen Inc. have showcased contrasting trajectories in their cost of revenue. AstraZeneca's cost of revenue surged by approximately 38% over this period, peaking in 2021 with a remarkable 124% increase compared to 2014. This reflects their aggressive expansion and investment in new drug development. In contrast, Biogen Inc. maintained a more stable cost structure, with a modest 116% increase from 2014 to 2023, highlighting their focus on operational efficiency.

The data reveals AstraZeneca's strategic shift in 2021, likely driven by their COVID-19 vaccine production, while Biogen's steady growth underscores their commitment to core therapeutic areas. As these two giants continue to navigate the competitive landscape, their cost efficiency strategies will be pivotal in shaping their future success.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025